What do systematic reviews say?

Summary of findings: bevacizumab vs placebo

The review found no eligible studies for this question.

• Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: bevacizumab vs placebo

The review found no eligible studies for this question.

• Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Edaravone plus corticosteroids vs corticosteroids

Edaravone plus corticosteroids showed no clear difference in reduction in oedema (T2 hyperintensity) compared with corticosteroids (low certainty).

• Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery 2018 · Cochrane Headline outcomes only
  MD 3.03
  1 study · 137 participants
  Low

Edaravone plus corticosteroids vs corticosteroids

Edaravone plus corticosteroids showed no clear difference in reduction in post‐gadolinium enhancement compared with corticosteroids (low certainty).

• Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery 2018 · Cochrane Headline outcomes only
  MD 0.47
  1 study · 137 participants
  Low

Edaravone plus corticosteroids vs corticosteroids

Edaravone plus corticosteroids may leads to higher improvement in LENT/SOMA compared with corticosteroids (low certainty).

• Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery 2018 · Cochrane Headline outcomes only
  OR 2.51
  1 study · 137 participants
  Low

Summary of findings: Aminosalicylates vs placebo

The review found no eligible studies for this question.

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Aminosalicylates vs placebo

Summary of findings: Aminosalicylates probably leads to higher acute and late GI toxicity (grade 2+) compared with placebo (moderate certainty).

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  RR 1.02 [1.22, 1.45]
  2 studies · 143 participants
  Moderate

Summary of findings: Aminosalicylates vs placebo

The review found no eligible studies for this question.

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Aminosalicylates vs placebo

The review found no eligible studies for this question.

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sucralfate vs placebo

The review found no eligible studies for this question.

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sucralfate vs placebo

Summary of findings: Sucralfate showed no clear difference in acute and late GI toxicity (grade 2+) [acute = during RT; late = 6… compared with placebo (moderate certainty).

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  RR 1.07 [0.83, 1.39]
  1 study · 335 participants
  Moderate

Sucralfate vs placebo

Summary of findings: Sucralfate may leads to lower diarrhoea (grade 2+) [during RT] compared with placebo (low certainty).

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  RR 0.81
  4 studies · 284 participants
  Low

Sucralfate vs placebo

The review found no eligible studies for this question.

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention diet vs usual on‐treatment diet

The review found no eligible studies for this question.

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention diet vs usual on‐treatment diet

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 50 participants
  Low

Intervention diet vs usual on‐treatment diet

The review found no eligible studies for this question.

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention diet vs usual on‐treatment diet

Summary of findings: Diet interventions showed no clear difference in diarrhoea (grade 2+) compared with usual on‐treatment diet (low certainty).

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  RR 0.79 [0.45, 1.38]
  1 study · 50 participants
  Low

Intervention diet vs usual on‐treatment diet

Summary of findings: Diet interventions showed no clear difference in QOL scores (IBDQ) (higher scores better) compared with usual on‐treatment diet (low certainty).

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  MD 4.6
  1 study · 50 participants
  Low
• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 119 participants
  GRADE not reported
• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  MD 2.4
  1 study · 76 participants
  Low

Intervention diet vs usual on‐treatment diet

The review found no eligible studies for this question.

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention diet vs usual on‐treatment diet

Summary of findings: Diet interventions showed no clear difference in diarrhoea (grade 1+) compared with usual on‐treatment diet (low certainty).

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  RR 0.74 [0.45, 1.23]
  1 study · 119 participants
  Low